LSIPR 50 2018: It’s not like selling cars

Managing and licensing the IP portfolio of a biomedical research centre as prestigious as the Broad Institute of MIT and Harvard may come with any number of challenges, but for Issi Rozen there is one key question he tackles in his day-to-day work as chief business officer: how can the Broad’s proprietary technology have the maximum impact possible, in a responsible way?